SEC Form 4 · accession 0001209191-15-069493
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yuchun Lee
Director
Period of report
Sep 1, 2015
Accepted (ET)
Sep 3, 2015 · 5:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2015 | M | 1,333 | $57.27 | A | 1,333 | D | |
| Common StockF2,F3 | Sep 1, 2015 | S | 100 | $123.92 | D | 1,233 | D | |
| Common StockF2,F4 | Sep 1, 2015 | S | 825 | $125.35 | D | 408 | D | |
| Common StockF2,F5 | Sep 1, 2015 | S | 200 | $126.32 | D | 208 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF6 | $57.27 | Sep 1, 2015 | A | 1,333 | A | — | Sep 13, 2022 | Common Stock | 1,333 | 28,667 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- F2Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $123.92 (range $123.92 to $123.92).
- F4Open market sales reported on this line occurred at a weighted average price of $125.35 (range $125.01 to $125.81).
- F5Open market sales reported on this line occurred at a weighted average price of $126.32 (range $126.25 to $126.38).
- F6The option vests in 16 quarterly installments from 9/14/2012.